Dose response and pharmacokinetics of tofacitinib (CP-690,550), an oral janus kinase inhibitor, in the treatment of chronic plaque psoriasis

CPT: Pharmacometrics and Systems Pharmacology

Volumn 2, Issue 5, 2013, Pages

  Tan, H ^a   Gupta, P ^a   Harness, J ^b   Wolk, R ^a   Chapel, S ^c   Menter, A ^d   Strober, B ^e   Langley, R G ^f   Krishnaswami, S ^a   Papp, K A ^g  

^a PFIZER INC   (United States)

^b NOVARTIS PHARMA AG   (Switzerland)

^c ANN ARBOR PHARMACOMETRICS GROUP   (United States)

^d BAYLOR RESEARCH INSTITUTE   (United States)

^e UNIVERSITY OF CONNECTICUT SCHOOL OF MEDICINE   (United States)

^f DALHOUSIE UNIVERSITY   (Canada)

^g PROBITY MEDICAL RESEARCH   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

PLACEBO; TOFACITINIB;

ARTICLE; BAYES THEOREM; BODY WEIGHT; CHRONIC DISEASE; CONTROLLED STUDY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; HUMAN; MAJOR CLINICAL STUDY; MAXIMUM PLASMA CONCENTRATION; MULTICENTER STUDY; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PSORIASIS VULGARIS; RANDOMIZED CONTROLLED TRIAL;

EID: 84881183888     PISSN: None     EISSN: 21638306     Source Type: Journal    
DOI: 10.1038/psp.2013.22     Document Type: Article

References (25)

1. Boy, M.G. et al. Double-blind, placebo-controlled, dose-escalation study to evaluate the pharmacologic effect of CP-690,550 in patients with psoriasis. J. Invest. Dermatol. 129, 2299-2302 (2009).
2. Gupta, P., Krishnaswami, S. & Harness, J. Development and application of a model-based decision criterion for a laboratory endpoint to facilitate tofacitinib Phase 3 dose selection. Clin. Pharmacol. Ther. 91, S94 (2012), abstract OIII-A-2.
3. Gieschke, R. & Steimer, J.L. Pharmacometrics: modelling and simulation tools to improve decision making in clinical drug development. Eur. J. Drug Metab. Pharmacokinet. 25, 49-58 (2000).
4. Miller, R. et al. How modeling and simulation have enhanced decision making in new drug development. J. Pharmacokinet. Pharmacodyn. 32, 185-197 (2005).
5. Comets, E. & Zohar, S. A survey of the way pharmacokinetics are reported in published phase I clinical trials, with an emphasis on oncology. Clin. Pharmacokinet. 48, 387-395 (2009).
6. Puig, L. Obesity and psoria is: body weight and body mass index influence the response to biological treatment. J. Eur. Acad. Dermatol. Venereol. 25, 1007-1011 (2011).
7. Fantuzzi, G. Adipose tissue in the regulation of inflammation. Immun. Endoc. Metab. Agents Med. Chem. 7, 129-136 (2007).
8. Feuerer, M. et al. Lean, but not obese, fat is enriched for a unique population of regulatory T cells that affect metabolic parameters. Nat. Med. 15, 930-939 (2009).
9. Tilg, H. & Moschen, A.R. Adipocytokines: mediators linking adipose tissue, inflammation and immunity. Nat. Rev. Immunol. 6, 772-783 (2006).
10. Papp, K.A. et al. Efficacy and safety of tofacitinib, an oral Janus kinase inhibitor, in the treatment of psoriasis: a Phase 2b randomized placebo-controlled dose-ranging study. Br. J. Dermatol. 167, 668-677 (2012).
11. Macheras, P. & Iliadis, A. Modeling in Biopharmaceutics, Pharmacokinetics and Pharmacodynamics: Homogeneous and Heterogeneous Approaches. (Springer, New York, 2006).
12. Tan, H., Gruben, D., French, J. & Thomas, N. A case study of model-based Bayesian dose response estimation. Stat. Med. 30, 2622-2633 (2011).
13. Gordon, K.B. et al. Clinical response to adalimumab treatment in patients with moderate to severe psoriasis: double-blind, randomized controlled trial and open-label extension study. J. Am. Acad. Dermatol. 55, 598-606 (2006).
14. Leonardi, C.L. et al.; Etanercept Psoriasis Study Group. Etanercept as monotherapy in patients with psoriasis. N. Engl. J. Med. 349, 2014-2022 (2003).
15. Leonardi, C.L. et al.; PHOENIX 1 study investigators. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1). Lancet 371, 1665-1674 (2008).
16. Papp, K.A. et al.; Etanercept Psoriasis Study Group. A global phase III randomized controlled trial of etanercept in psoriasis: safety, efficacy, and effect of dose reduction. Br. J. Dermatol. 152, 1304-1312 (2005).
17. Papp, K.A. et al.; PHOENIX 2 study investigators. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2). Lancet 371, 1675-1684 (2008).
18. Saurat, J.H. et al.; CHAMPION Study Investigators. Efficacy and safety results from the randomized controlled comparative study of adalimumab vs. methotrexate vs. placebo in patients with psoriasis (CHAMPION). Br. J. Dermatol. 158, 558-566 (2008).
19. Fleischmann, R. et al. Phase 2B dose-ranging study of the oral JAK inhibitor tofacitinib (CP-690,550) or adalimumab monotherapy versus placebo in patients with active rheumatoid arthritis with an inadequate response to DMARDs. Arthritis Rheum. (2011); e-pub ahead of print 27 September 2011.
20. Kremer, J.M. et al. A phase IIb dose-ranging study of the oral JAK inhibitor tofacitinib (CP- 690,550) versus placebo in combination with background methotrexate in patients with active rheumatoid arthritis and an inadequate response to methotrexate alone. Arthritis Rheum. 64, 970-981 (2012).
21. Kremer, J.M. et al. The safety and efficacy of a JAK inhibitor in patients with active rheumatoid arthritis: results of a double-blind, placebo-controlled phase IIa trial of three dosage levels of CP-690,550 versus placebo. Arthritis Rheum. 60, 1895-1905 (2009).
22. Griffiths, C.E. et al.; ACCEPT Study Group. Comparison of ustekinumab and etanercept for moderate-to-severe psoriasis. N. Engl. J. Med. 362, 118-128 (2010).
23. Reich, K. et al. A 52-week trial comparing briakinumab with methotrexate in patients with psoriasis. N. Engl. J. Med. 365, 1586-1596 (2011).
24. Lunn, D., Spiegelhalter, D., Thomas, A. & Best, N. The BUGS project: evolution, critique and future directions. Stat. Med. 28, 3049-3067 (2009).
25. Gelman, J.B., Carlin, J.B., Stern, H.S. & Rubin, D.B. Bayesian Data Analysis 2 edn. (Chapman & Hall/CRC, London, 2003).